This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Ovarian Cancer  • Alert me on articles by topic  Social Bookmarking   What's this?

James Allen Roberts, MD, MS

JAMA. 1998;280:739.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This year 25400 women will be told that they have ovarian cancer. Over the next 3 to 5 years 14500 of them will die from their disease.¹ Although these statistics are disturbing, they do not provide a complete image of what this truly means in terms of human suffering. Most of these women will undergo several major surgeries, multiple courses of chemotherapy treatment with their associated toxic effects, and several bouts of bowel dysfunction. They also will endure the psychological trauma of battling cancer before they die of their disease. In nearly every case, this morbidity and mortality are the result of a late diagnosis, with more than 50% of these women already having advanced to stage III or IV at the first physical signs of disease. An estimated 90% of these women (at least 13100) might be spared all of this, with no change . . . [Full Text of this Article]

From the Department of Gynecology and Obstetrics, Stanford University School of Medicine, Stanford, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
, , , , , , , , , and
JAMA. ;280():719-723.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Potential New Marker for Ovarian Cancer
JWatch General 1998;1998:2-2.
FULL TEXT